The latest price target for Olema Pharmaceuticals (NASDAQ:OLMA) was reported by HC Wainwright & Co. on December 12, 2024. The analyst firm set a price target for $0.00 expecting OLMA to fall to within 12 months (a possible -100.00% downside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Olema Pharmaceuticals (NASDAQ:OLMA) was provided by HC Wainwright & Co., and Olema Pharmaceuticals reiterated their buy rating.

The last upgrade for Olema Pharmaceuticals inc happened on June 10, 2022 when HC Wainwright & Co. raised their price target to N/A. HC Wainwright & Co. previously had a neutral for Olema Pharmaceuticals inc.

There is no last downgrade for Olema Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Olema Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Olema Pharmaceuticals was filed on December 12, 2024 so you should expect the next rating to be made available sometime around December 12, 2025.

While ratings are subjective and will change, the latest Olema Pharmaceuticals (OLMA) rating was a reiterated with a price target of $0.00 to $0.00. The current price Olema Pharmaceuticals (OLMA) is trading at is $6.25, which is out of the analyst’s predicted range.